Dr Clare van Halsema

Similar documents
Downloaded from:

TB prevention studies in PLHIV: recent updates and what can they tell us for the future?

Overview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions

Abstract. n engl j med 370;4 nejm.org january 23,

The health of the South African mining workforce: trends, progress and challenges Jill Murray and Zodwa Ndlovu

Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial

Predictors of drug sensitive tuberculosis treatment outcomes among hospitalised

What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM

Modeling the diagnosis of HIVassociated

TB in Corrections Phoenix, Arizona

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

APSR RESPIRATORY UPDATES

Downloaded from:

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Latent tuberculosis infection

Laboratory Reporting of Tuberculosis Test Results and Patient Treatment Initiation in California

Investigation of Contacts of Persons with Infectious Tuberculosis, 2005

Contact Investigation Salina, Kansas

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

Annual Epidemiological Report

C R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership

Urinary TB diagnostics in HIV

INDEX CASE INFORMATION

Supplementary appendix

Diagnosis and Medical Management of Latent TB Infection

TB Prevention Who and How to Screen

Isoniazid preventive therapy for HIV+:

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

10. TB and HIV Infection

Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.

TB in the Patient with HIV

Northwestern Polytechnic University

Clinical Study Performance of Clinical Algorithms for Smear-Negative Tuberculosis in HIV-Infected PersonsinHoChiMinhCity,Vietnam

COHORT STUDY OF HIV POSITIVE AND HIV NEGATIVE TUBERCULOSIS in PENANG HOSPITAL: COMPARISON OF CLINICAL MANIFESTATIONS

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI

Annual Tuberculosis Report Oregon 2007

Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal

ADDRESSING MDR TB IN THE CONTEXT OF HIV: Lessons from Lesotho. Dr Hind Satti PIH Lesotho Director MDR-TB program

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

TB Clinical Guidelines: Revision Highlights March 2014

The diagnosis of active TB

MEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment

RISK FACTORS FOR RECURRENCE OF PULMONARY TUBERCULOSIS IN NAN PROVINCE

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa

INTENSIFIED TB CASE FINDING

TB Contact Investigation Basics

The Impact of Isoniazid Preventive Therapy and Antiretroviral Therapy on Tuberculosis Incidence in Children Living with HIV in Vietnam

Lack of Weight Gain and Relapse Risk in a Large Tuberculosis Treatment Trial

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Time to Sputum Culture Conversion, identifying independent modifiable risk factors

Diagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre

Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB- IRIS)

Karen R Steingart, MD, MPH Madhu Pai, MD, PhD David Dowdy, MD Berlin, 11 November 2010

Contact Investigation

TB-Free California: How close are we? How can we get closer?

Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan

has the following disclosures to make:

CORRELATES OF DELAYED PULMONARY TUBERCULOSIS DIAGNOSIS AMONG HIV-INFECTED PULMONARY TUBERCULOSIS SUSPECTS IN A. Respicious L Boniface

Tuberculosis in England 2018 report (presenting data to end of 2017) Tables and figures slide set

TUBERCULOSIS CONTACT INVESTIGATION

Immune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale

Downloaded from:

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment

World Health Organization HIV/TB Facts 2011

Contact Investigation San Antonio, Texas January 14-15, 2013

A household survey on screening practices of household contacts of smear positive tuberculosis patients in Vietnam

TB Intensive San Antonio, Texas December 1-3, 2010

Treatment of Active Tuberculosis

TB Nurse Case Management San Antonio, Texas March 7 9, TB Infection Control Robert Petrossian March 8, 2012

Errors in Dx and Rx of TB

Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation?

LTBI Treatment and Anti TNF alpha

TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks

Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment

Interventions to improve screening for latent TB: effectiveness and outcomes

The clinical utility of the urine based lateral flow lipoarabinomannan (LF-LAM) assay in HIV infected adults in Myanmar.

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Yakima Health District BULLETIN

MEMORANDUM. Re: Guidance for follow-up of newly-arrived Individual with a Class B1 Tuberculosis Extrapulmonary Tuberculosis

Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study

TB/HIV prevention. Implementation science and TB prevention

Evidence on IGRAs in Low & Middle Income Countries. Madhukar Pai, MD, PhD McGill University, Montreal

Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi

Title: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection

Chapter 22. Pulmonary Infections

Diagnosis and Treatment of Tuberculosis, 2011

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

Short Course Treatment for MDR TB

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease

August 30, 1991 / 40(34);

The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study

What Drug Treatment Centers Can do to Prevent Tuberculosis

TB Intensive San Antonio, Texas May 7-10, 2013

TB Infection Control Policy. Scaling-up the implementation of collaborative TB/HIV activities in the Region of the

Transcription:

19 th Annual Conference of the British HIV Association (BHIVA) Dr Clare van Halsema North Manchester General Hospital 16-19 April 2013, Manchester Central Convention Complex

The effect of antiretroviral therapy on chest radiograph appearance in HIV-associated pulmonary tuberculosis Clare van Halsema, Violet Chihota, Tom Gorsuch, James Lewis, Elizabeth George, Katherine Fielding, Gavin Churchyard, Alison Grant 19 th BHIVA, Manchester, April 2013

Background Clinical features of tuberculosis (TB) vary with the degree of HIV-associated immunosuppression (CD4 count) Positive sputum smears and lung cavitation are associated with TB transmission We have previously shown that combination antiretroviral therapy (cart) does not affect the proportion smear positive, independently of CD4 count 1 The effect of cart on lung cavitation, independent of CD4 count, is unknown and relevant to TB control 1 van Halsema et al, CROI 2010, abstract P-126

Aim To examine the effect of cart on chest radiograph (CXR) appearance, particularly cavitation, as a marker of TB infectiousness

Setting TB case notification rates 2450 3000/100,000/year in 2008 1 High HIV prevalence (around 29% 2 ) on background of high TB incidence due to silicosis Thibela TB was a cluster-randomised trial of a mass TB prevention intervention TB screening and community-wide isoniazid preventive therapy were delivered in intervention clusters 1 van Halsema et al, Int J Tuberc Lung Dis 2012 2 Lewis et al, Am J Resp Crit Care Med 2009

Thibela TB study design Baseline TB prevalence survey Enrolment in intervention clusters Nine months to complete IPT in intervention clusters 12 months measurement period for primary outcome Final TB prevalence survey Data extraction from medical records for all incident TB episodes in intervention and control clusters throughout study Adapted from Fielding et al, Contemp Clin Trials 2011

Methods Cross-sectional analysis of TB episodes from 2004-9 CXRs read by investigators masked to HIV and cart status Analysis included individuals with: Known HIV and cart status Pulmonary +/- disseminated or extrapulmonary disease Sputum smear and/or M. tuberculosis culture positive Available CXR within 2 months of TB treatment start Those on cart <=90 days analysed separately in view of possible immune reconstitution inflammatory syndrome

Results: numbers included 5957 TB episodes from 5858 individuals HIV status established for 2741/5858 (47%) HIV and cart status established for 1589/5858 (27%) 1086/1589 (68%) had pulmonary disease (125/1086 [12%] also disseminated or extrapulmonary) 533/1086 (49%) had available CXR 4 smear and culture negative 24 CXR taken >2/12 from TB treatment start 495 included in analysis

Results: study group characteristics Variable Number 1 (% of 495) Male gender 481/494 (97%) Median age 43 years (IQR 38, 48) Living in hostel/informal housing 343/492 (71%) First TB episode 318/487 (65%) Sputum smear positive 370 (75%) M. tuberculosis culture positive 385/423 (91%) 1 Denominator given where some data missing 2 IQR = interquartile range

Results: HIV and cart status Group Number Median CD4 count (cells/µl; IQR 1 ; number with known CD4 count) HIV-negative 156 - HIV-positive not on cart 224 139* (76, 220; n=201) HIV-positive on cart <=90 days 28 187 (90, 339; n=26) HIV-positive on cart >90 days 87 219* (125, 333; n=80) Total 495 149 (86, 263; n=307) *Difference in CD4 distribution between those on cart >90 days versus not on cart: p<0.002 by Kruskal-Wallis test 1 IQR = interquartile range

0 Proportion smear positive.2.4.6.8 Results: sputum smear status 80/97 Proportion smear positive by CD4 count 61/97 48/75 26/38 <100 100-199 200-349 350+ Proportions smear-positive, regardless of cart status, varied non-linearly with CD4 count among HIV-positive individuals (chi 2 p=0.01)

Results: Bacillary density and cavitation Cavitation Smear grade: number (% of row total) Negative Scanty+ 1+ 2+ 3+ Total No 85 (31) 4 (2) 96 (35) 39 (14) 48 (18) 272 (100) Yes 35 (16) 3 (1) 63 (29) 37 (17) 80 (37) 218 (100) Total 120 (25) 7 (1) 159 (33) 76 (16) 128 (26) 490 (100) Cavitation is associated with higher sputum bacillary density (chi 2 p<0.001)

0 0.2.4.6.8 Proportion of group with lung cavitation.2.4.6 Results: lung cavitation Proportion with lung cavitation by HIV and cart status Proportion with lung cavitation by CD4 category * * HIV no cart On cart <=90d On cart >90d HIV- <100 100-199 200-349 350+ Comparing HIV-positive on cart >90 days vs. not on cart, odds ratio (OR) for cavitation 1.85 (1.11-3.09); p=0.02 Cavitation linearly associated with CD4 count: OR for cavitation 1.61 (1.27-2.06) for each increase in CD4 category (p<0.001)

Results: multivariable analysis Model Number of TB episodes included OR for lung cavitation On cart >90 days vs. off cart p-value 2 cart status (unadjusted) 311 1.85 (1.11-3.09) 0.02 cart status, adjusted for CD4 281 1.66 (0.95-2.91) 0.08 cart status, adjusted for CD4, age, episode type 1 259 1.50 (0.82-2.72) 0.19 cart not associated with lung cavitation after adjustment in multivariable model 1 Episode type = First or subsequent TB episode for that individual 2 p-values from Wald test in multivariable model

Study limitations Observational study with possible bias HIV testing in those with more severe disease cart used in group with specific characteristics Missing data possibly associated with HIV-related outcomes Gold mining workforce with particular characteristics, eg silicosis, but internal comparisons still valid and relevant to other settings Some variation in timing of CD4, CXR, smear measurement could affect estimation of ORs

Conclusions High proportions smear positive in lowest CD4 stratum cart use was not associated with lung cavitation after adjustment for CD4 count Overall, cart is likely to increase infectiousness of TB through CD4 recovery This has implications for TB control in high HIV-prevalence areas, including nosocomial settings Data may be of use in modelling the impact of widespread cart use on TB transmission

Acknowledgements Funding from: Gilead/BHIVA SpR research award 2009 The Colt Foundation, UK Bill and Melinda Gates Foundation and CREATE (primary funder for Thibela TB) Staff of Thibela TB and mine health services

The effect of antiretroviral therapy on chest radiograph appearance in HIV-associated pulmonary tuberculosis Clare van Halsema, Violet Chihota, Tom Gorsuch, James Lewis, Elizabeth George, Katherine Fielding, Gavin Churchyard, Alison Grant 19 th BHIVA: Manchester, April 2013